SFRP1-Mediated Inhibition of Wnt/β-Catenin Pathway Attenuates Oral Submucous Fibrosis: Mechanistic Insights and Research Implications

Study Background and Research Question

Oral submucous fibrosis (OSF) is a chronic, progressive, and precancerous condition characterized by submucosal fibrosis, collagen deposition, and eventual mucosal atrophy, leading to significant morbidity and a risk of malignant transformation. OSF is particularly prevalent in certain geographic regions, with areca nut chewing identified as a major etiological factor (Zhou et al., 2024). Despite the identification of multiple biomarkers and experimental therapies, clinical management remains limited to conservative measures aimed at symptom control. There is a pressing need to elucidate the molecular mechanisms driving OSF, particularly the interplay between inflammation, immune cell infiltration, and fibrogenic signaling pathways.

The Wnt/β-catenin signaling pathway is fundamental to embryonic development and tissue homeostasis but, when aberrantly activated, is implicated in pathological fibrosis across organ systems. Previous work has highlighted secreted frizzled-related protein 1 (SFRP1) as a negative regulator of Wnt/β-catenin signaling with putative roles in tumor suppression and immune modulation. However, its specific function within the OSF disease context remained poorly defined.

Key Innovation from the Reference Study

The central innovation of the reference study lies in its demonstration that SFRP1 acts as a dual regulator in OSF: it both inhibits the Wnt/β-catenin pathway and reduces neutrophil infiltration within fibrotic oral tissue. This dual mechanism—fibrosis suppression and immunomodulation—was systematically interrogated in an arecoline-induced mouse model of OSF. Through correlative and interventional studies, the research uncovers a significant inverse relationship between SFRP1 expression and both Wnt/β-catenin signaling activity and neutrophil recruitment in the oral mucosa. Furthermore, forced overexpression of SFRP1 not only decreased fibrotic markers but also mitigated inflammatory cell infiltration, thereby attenuating disease progression.

Methods and Experimental Design Insights

The research utilized a robust arecoline-induced OSF mouse model, which recapitulates key features of human disease including submucosal fibrosis and increased neutrophil infiltration. Quantitative immunohistochemistry and biochemical assays were employed to assess the levels of SFRP1, β-catenin, Cyclin D1, c-myc, and markers of neutrophil presence within oral mucosal tissue (OMT). Pearson’s correlation analysis was applied to delineate associations among SFRP1 expression, Wnt/β-catenin pathway activity, and immune cell infiltration. Crucially, the study incorporated both gain-of-function (SFRP1 overexpression) and pharmacological activation of the Wnt/β-catenin pathway to dissect causality. In vitro, pathway-specific activators were used to evaluate whether SFRP1’s effects could be reversed, thereby confirming the specificity of its action on Wnt signaling in the context of OSF.

Protocol Parameters

• Arecoline-induced OSF model: Chronic arecoline administration to mice, modeling human OSF etiology and progression.
• SFRP1 overexpression: Genetic or vector-mediated upregulation in oral mucosal tissue to evaluate functional impact on fibrosis and immune infiltration.
• Immunohistochemical quantification: Assessment of fibrosis (collagen deposition), neutrophil infiltration, and expression of Wnt pathway-related proteins (β-catenin, Cyclin D1, c-myc).
• Pharmacological Wnt activation: Application of a Wnt/β-catenin pathway activator in vitro to test reversibility of SFRP1-mediated inhibition.
• Correlation analysis: Statistical evaluation of relationships between SFRP1 levels, Wnt/β-catenin activation, and neutrophil infiltration intensity.

Core Findings and Why They Matter

Compared with controls, OSF model mice displayed increased submucosal collagen deposition, higher neutrophil infiltration, and upregulated expression of Wnt/β-catenin pathway effectors (β-catenin, Cyclin D1, c-myc). SFRP1 expression was markedly reduced in OSF tissue, and its levels inversely correlated with both Wnt/β-catenin signaling and neutrophil presence. Importantly, SFRP1 overexpression led to:

• Significant reduction in oral mucosal fibrosis and collagen content.
• Decreased neutrophil infiltration, supporting an anti-inflammatory role.
• Suppressed expression of Wnt/β-catenin target genes.

Application of a Wnt/β-catenin pathway activator in vitro reversed the anti-fibrotic and anti-inflammatory effects of SFRP1, confirming that its protective actions in OSF are at least partly mediated via Wnt pathway inhibition. This mechanistic clarity positions SFRP1 as a central endogenous regulator of both fibrogenesis and immune cell recruitment in OSF (Zhou et al., 2024).

Comparison with Existing Internal Articles and Broader Wnt Pathway Context

These findings are consistent with and substantiate the conclusions presented in internal resources that highlight SFRP1’s role as a Wnt pathway inhibitor with significant anti-fibrotic and immunomodulatory effects. The translational value of Wnt/β-catenin pathway modulation is further discussed in articles such as "Strategic Modulation of Wnt/β-Catenin: HLY78 in Translational Research", which explores the mechanistic interplay between Wnt pathway activation and fibrotic disease models. Notably, these resources also detail the use of small-molecule modulators like HLY78 to probe canonical Wnt signaling in developmental and fibrotic contexts.

The current study’s focus on SFRP1-mediated inhibition complements the research utility of Wnt/β-catenin pathway activators, enabling a comparative framework for dissecting pathway dynamics. For instance, in contrast to SFRP1’s suppressive effects, HLY78 serves as a potent pathway activator and has been used to model enhanced Wnt signaling during zebrafish embryogenesis and to induce hematopoietic stem cell markers such as cmyb and runx1.

Limitations and Transferability

While the arecoline-induced mouse model provides valuable insights into OSF pathogenesis and SFRP1 function, certain limitations warrant consideration. First, species-specific differences may affect the direct translatability of results to human OSF. Second, the study focused on acute and subchronic endpoints; the long-term effects of SFRP1 modulation, particularly in malignant transformation, remain to be explored. The use of pharmacological Wnt activators in vitro establishes pathway specificity but may not fully recapitulate in vivo signaling complexity. Additionally, the dual role of the Wnt/β-catenin pathway in tissue homeostasis and regeneration necessitates careful balancing in any prospective therapeutic modulation.

Despite these caveats, the study provides a robust experimental paradigm for evaluating both endogenous (SFRP1) and exogenous (small-molecule) Wnt pathway modulators in fibrotic and inflammatory disease models.

Research Support Resources

Researchers interested in further dissecting Wnt/β-catenin pathway dynamics, or modeling the effects of pathway activation in fibrosis or developmental biology, may consider using HLY78 (SKU C5433), a well-characterized small-molecule Wnt/β-catenin pathway modulator. HLY78 enables precise activation of Wnt signaling in a ligand-dependent manner by targeting the Axin-LRP6 interaction, and has been employed in embryonic development research and in studies of hematopoietic stem cell marker induction. For workflow-specific guidance, see the product information and consult recent literature on Wnt pathway modulators in fibrotic disease modeling.